NO20032542L - Dempede anti-CD28-antistoffer og anvendelse derav - Google Patents
Dempede anti-CD28-antistoffer og anvendelse deravInfo
- Publication number
- NO20032542L NO20032542L NO20032542A NO20032542A NO20032542L NO 20032542 L NO20032542 L NO 20032542L NO 20032542 A NO20032542 A NO 20032542A NO 20032542 A NO20032542 A NO 20032542A NO 20032542 L NO20032542 L NO 20032542L
- Authority
- NO
- Norway
- Prior art keywords
- antibodies
- attenuated anti
- attenuated
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Transplantation (AREA)
- Surgery (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25515500P | 2000-12-14 | 2000-12-14 | |
| PCT/US2001/047955 WO2002047721A1 (en) | 2000-12-14 | 2001-12-14 | Silensed anti-cd28 antibodies and use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20032542D0 NO20032542D0 (no) | 2003-06-05 |
| NO20032542L true NO20032542L (no) | 2003-08-07 |
Family
ID=22967074
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20032542A NO20032542L (no) | 2000-12-14 | 2003-06-05 | Dempede anti-CD28-antistoffer og anvendelse derav |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP1341553A4 (ko) |
| JP (1) | JP2004515243A (ko) |
| KR (1) | KR20040020866A (ko) |
| CN (1) | CN1272345C (ko) |
| AR (1) | AR031924A1 (ko) |
| AU (2) | AU2002226086C1 (ko) |
| BR (1) | BR0116686A (ko) |
| CA (1) | CA2432736A1 (ko) |
| CZ (1) | CZ20031909A3 (ko) |
| HU (1) | HUP0400697A3 (ko) |
| IL (1) | IL156262A0 (ko) |
| MX (1) | MXPA03005327A (ko) |
| NO (1) | NO20032542L (ko) |
| NZ (1) | NZ526569A (ko) |
| PL (1) | PL363239A1 (ko) |
| RU (1) | RU2261723C2 (ko) |
| WO (1) | WO2002047721A1 (ko) |
| ZA (1) | ZA200305384B (ko) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080095774A1 (en) * | 2001-02-16 | 2008-04-24 | Wyeth | Agents and Methods for Specifically Blocking CD28-Mediated Signaling |
| US7531168B2 (en) | 2001-02-16 | 2009-05-12 | Genetics Institute Llc | Method for downmodulating immune response in type I diabetes |
| BRPI0611901A2 (pt) | 2005-06-14 | 2012-08-28 | Amgen, Inc | composição, liofilizado, kit, e, processo para preparar uma composição |
| FR2951176A1 (fr) | 2009-10-09 | 2011-04-15 | Tcl Pharma | Ligands monovalents du recepteur cd28 humain |
| WO2011101791A1 (en) * | 2010-02-18 | 2011-08-25 | Tcl Pharma | Anti-cd28 humanized antibodies |
| AU2017345490B2 (en) | 2016-10-21 | 2022-07-07 | Amgen Inc. | Pharmaceutical formulations and methods of making the same |
| KR20210035805A (ko) | 2018-06-15 | 2021-04-01 | 플래그쉽 파이어니어링 이노베이션스 브이, 인크. | 세포후 신호전달 인자의 조절을 통한 면역 활성의 증가 |
| WO2020183471A1 (en) * | 2019-03-14 | 2020-09-17 | Biond Biologics Ltd. | A method for immunosuppression |
| MA55805A (fr) | 2019-05-03 | 2022-03-09 | Flagship Pioneering Innovations V Inc | Métodes de modulation de l'activité immunitaire |
| JP2023509359A (ja) | 2019-12-17 | 2023-03-08 | フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド | 鉄依存性細胞分解の誘導物質との併用抗癌療法 |
| CN116096906A (zh) | 2020-06-29 | 2023-05-09 | 旗舰创业创新五公司 | 工程化以促进萨诺传递的病毒及其在治疗癌症中的用途 |
| IL300666A (en) | 2020-08-19 | 2023-04-01 | Xencor Inc | ANTI–CD28 COMPOSITIONS |
| KR20230165276A (ko) | 2021-03-31 | 2023-12-05 | 플래그쉽 파이어니어링 이노베이션스 브이, 인크. | 타노트랜스미션 폴리펩티드 및 암의 치료에서의 이의 용도 |
| EP4363059A1 (en) | 2021-06-29 | 2024-05-08 | Flagship Pioneering Innovations V, Inc. | Immune cells engineered to promote thanotransmission and uses thereof |
| WO2024040195A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| WO2024077191A1 (en) | 2022-10-05 | 2024-04-11 | Flagship Pioneering Innovations V, Inc. | Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6641809B1 (en) * | 1990-03-26 | 2003-11-04 | Bristol-Myers Squibb Company | Method of regulating cellular processes mediated by B7 and CD28 |
-
2001
- 2001-12-14 AR ARP010105828A patent/AR031924A1/es unknown
- 2001-12-14 NZ NZ526569A patent/NZ526569A/en unknown
- 2001-12-14 BR BR0116686-7A patent/BR0116686A/pt not_active IP Right Cessation
- 2001-12-14 HU HU0400697A patent/HUP0400697A3/hu unknown
- 2001-12-14 AU AU2002226086A patent/AU2002226086C1/en not_active Ceased
- 2001-12-14 CA CA002432736A patent/CA2432736A1/en not_active Abandoned
- 2001-12-14 CZ CZ20031909A patent/CZ20031909A3/cs unknown
- 2001-12-14 CN CNB018226361A patent/CN1272345C/zh not_active Expired - Fee Related
- 2001-12-14 KR KR10-2003-7007798A patent/KR20040020866A/ko not_active Application Discontinuation
- 2001-12-14 MX MXPA03005327A patent/MXPA03005327A/es unknown
- 2001-12-14 EP EP01995504A patent/EP1341553A4/en not_active Withdrawn
- 2001-12-14 IL IL15626201A patent/IL156262A0/xx unknown
- 2001-12-14 PL PL01363239A patent/PL363239A1/xx not_active Application Discontinuation
- 2001-12-14 AU AU2608602A patent/AU2608602A/xx active Pending
- 2001-12-14 WO PCT/US2001/047955 patent/WO2002047721A1/en not_active Application Discontinuation
- 2001-12-14 RU RU2003121231/15A patent/RU2261723C2/ru not_active IP Right Cessation
- 2001-12-14 JP JP2002549291A patent/JP2004515243A/ja not_active Withdrawn
-
2003
- 2003-06-05 NO NO20032542A patent/NO20032542L/no not_active Application Discontinuation
- 2003-07-11 ZA ZA200305384A patent/ZA200305384B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NO20032542D0 (no) | 2003-06-05 |
| JP2004515243A (ja) | 2004-05-27 |
| CZ20031909A3 (cs) | 2003-11-12 |
| HUP0400697A2 (hu) | 2004-06-28 |
| HUP0400697A3 (en) | 2007-05-02 |
| CN1489473A (zh) | 2004-04-14 |
| IL156262A0 (en) | 2004-01-04 |
| RU2003121231A (ru) | 2005-02-10 |
| EP1341553A1 (en) | 2003-09-10 |
| MXPA03005327A (es) | 2004-12-03 |
| EP1341553A4 (en) | 2004-07-28 |
| RU2261723C2 (ru) | 2005-10-10 |
| KR20040020866A (ko) | 2004-03-09 |
| CA2432736A1 (en) | 2002-06-20 |
| ZA200305384B (en) | 2004-10-11 |
| AU2002226086C1 (en) | 2006-03-09 |
| CN1272345C (zh) | 2006-08-30 |
| PL363239A1 (en) | 2004-11-15 |
| NZ526569A (en) | 2005-07-29 |
| AU2002226086B2 (en) | 2005-08-25 |
| WO2002047721A1 (en) | 2002-06-20 |
| AR031924A1 (es) | 2003-10-08 |
| BR0116686A (pt) | 2003-12-30 |
| AU2608602A (en) | 2002-06-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY2019029I2 (el) | Anti-tnf αντισωματα, συνθεσεις, μεθοδοi και χρησεις | |
| NO20034405D0 (no) | Anti-ostepontin-antistoff og anvendelse derav | |
| IS6779A (is) | Mannlíkt mótefni gegn LT-beta-R | |
| DK1691837T3 (da) | IP-10-antistoffer og anvendelse heraf | |
| DK1417175T3 (da) | Substituerede dihydro-3-halo-1h-pyrazol-5-carboxylater og fremstillingog anvendelse heraf | |
| DK1122244T3 (da) | Uracilforbindelser og anvendelse deraf | |
| NO20030614D0 (no) | Anti-IL-12-antistoffer, sammensetninger, fremgangsmåter og anvendelser | |
| IS7041A (is) | 5-HT viðtakabindlar og notkun þeirra | |
| NO20021449D0 (no) | Substituerte 2-tio-3,5-dicyano-4-aryl-6-aminopyridiner og anvendelse derav | |
| TWI316088B (en) | Anti-tnf alpha antibodies and their uses | |
| DK1711207T3 (da) | Interferon-alpha-antistoffer og anvendelse heraf | |
| NO20033418D0 (no) | Immunregulatoriske antistoffer og anvendelse derav | |
| IS6411A (is) | Kaspasa tálmar og notkun þeirra | |
| NO20033456L (no) | Modifiserte og stabiliserte GDF-propeptider og anvendelse derav | |
| NO20033387L (no) | Modifiserte antistoffer og fremgangsmåter for anvendelse | |
| DK1278763T3 (da) | 3-Nitrogen-6,7-dioxygensteroider og anvendelser relateret dertil | |
| NO20032542L (no) | Dempede anti-CD28-antistoffer og anvendelse derav | |
| DK1322597T3 (da) | Fremgangsmåde og intermediære | |
| DK1140952T3 (da) | Phosphororganiske forbindelser og anvendelse heraf | |
| FI20000432A (fi) | Putkiliitos | |
| NO20032821D0 (no) | Sea-trosy og beslektede fremgangsmåter | |
| DK1317478T3 (da) | Skelnen mellem GnRH-I og GnRH-II | |
| IS6570A (is) | Þrýstingslækkandi miðlar og notkun | |
| FI20000433A0 (fi) | Putkiliitos | |
| ITPD20000192A0 (it) | Anticorpi policlonali |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| CREP | Change of representative |
Representative=s name: PLOUGMANN 6 VINGTOFT POSTBOKS 1003 SENTRUM OSLO, 0 |
|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |